Cardinal to Sell $1.8 Billion Contract Services Unit - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cardinal to Sell $1.8 Billion Contract Services Unit


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Dublin, OH (Nov. 30)Cardinal Health (www.cardinal.com) has announced plans to divest its Pharmaceutical Technologies and Services (PTS) segment, “a business that manufactures or packages 100 billion doses of medication every year for pharmaceutical and biotech firms, employs approximately 10,000 at more than 30 facilities worldwide and generates $1.8 billion in revenue,” according to a company statement.

The portion of PTS slated for sale develops and manufactures oral and sterile medication in nearly all dosage forms, and holds patents for softgel and “Zydis” fast-dissolve technologies.  The business “is also the largest contract packager of pharmaceuticals,” according to Cardinal.  The spun-out business should generate more than $300 million in earnings before interest, taxes, depreciation and amortization, according to Cardinal's estimates.

Cardinal will retain PTS's Martindale and Beckloff Associates groups, “two businesses that support the generic pharmaceutical market.”  Martindale develops generic, intravenous medicines, supporting Cardinal's hospital business, and  Beckloff provides regulatory consulting services, including for generic products.  Combined, the retained businesses have approximately 400 employees in the US and UK.

The sale will help Cardinal focus on serving health-care provider customers, such as hospitals and pharmacies, and on its generics business.

In a Nov. 30 conference call, Cardinal CEO R. Kerry Clark said that the company hopes to close the sale around the middle of 2007. He declined to say whether the company was currently in discussions with a potential buyer.

“In the coming years, Cardinal Health will focus more on our products and services that help providers improve the safety and productivity of health care,” said Clark in the prepared statement.  “While synergies clearly exist between PTS and our other businesses, we believe there is greater customer and shareholder value in the expansion of our supply-chain and medical and clinical products businesses domestically and internationally.  These segments align with our core competencies and customers, and we see significant opportunities for future growth and improved return on capital.”

The company expects to use proceeds of the sale to repurchase Cardinal Health shares.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here